21
Participants
Start Date
April 25, 2013
Primary Completion Date
September 21, 2020
Study Completion Date
September 21, 2020
ABI-007
Starting dose of ABI-007 is 150 mg/m2 administered by vein on days 1, 8, 15 every 28 days. The cycle length for ABI-007 is 28 days.
Ipilimumab
3 mg/kg by vein over 90 minutes on day 1. Ipilimumab dose repeated every 21 days for a total of 4 doses.
Phone Call
Every 2 months for 6 months, then every 3 months for up to 2 years, participant contacted by telephone. Each call should last about 5 minutes.
University of Texas MD Anderson Cancer Center, Houston
Collaborators (1)
Celgene
INDUSTRY
M.D. Anderson Cancer Center
OTHER